Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18501426 | 1.00 | PDK1 (0.50) | PDK1ALDH1A1MAPTLIMK1KDM4E | |
| SCHEMBL14328268 | 1.00 | PDK1 (0.50) | PDK1ALDH1A1MAPTLIMK1KDM4E | |
| SCHEMBL24565374 | 0.89 | ALDH1A1 (0.47) | PDK1ALDH1A1MAPTKDM4EKMT2A | |
| SCHEMBL141713 | 0.89 | ALDH1A1 (0.47) | PDK1ALDH1A1MAPTKDM4EKMT2A | |
| SCHEMBL5483 | 0.89 | ALDH1A1 (0.51) | PDK1ALDH1A1MAPTKDM4EKMT2A | |
| SCHEMBL9097897 | 0.88 | ALDH1A1 (0.49) | PDK1ALDH1A1KDM4EKMT2AMEN1 | |
| SCHEMBL19816460 | 0.86 | PPM1B (0.41) | PDK1ALDH1A1MAPTLIMK1KDM4E | |
| SCHEMBL19816450 | 0.86 | PPM1B (0.41) | PDK1ALDH1A1MAPTLIMK1KDM4E | |
| Ethylene SCHEMBL4705578 | 0.85 | ALDH1A1 (0.49) | PDK1ALDH1A1MAPTKDM4EKMT2A | |
| SCHEMBL871448 | 0.84 | ALDH1A1 (0.50) | PDK1ALDH1A1MAPTKDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 202 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107328-A1 | AGONISTS OF PARATHYROID HORMONE 1 AND INCRETIN RECEPTORS | SEPTERNA, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20260132109-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2026-05-14 | — | — | US | disclosed |
| WO-2026043617-A1 | COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF HEALTH CONDITIONS AND DRUG SCREENING | REGLAGENE, INC. (US) | 2026-02-26 | — | — | WO | disclosed |
| US-12528781-B2 | Heterocyclic GLP-1 agonists | GASHERBRUM BIO, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-12503436-B2 | Compounds and compositions for treating conditions associated with STING activity | NOVARTIS PHARMA AG (CH) | 2025-12-23 | — | — | US | disclosed |
| EP-4192831-B1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO INC (US) | 2025-10-22 | — | — | EP | disclosed |
| EP-4634159-A1 | SULFOXIMINES AS INHIBITORS OF NAV1.8 | Grünenthal GmbH (DE) | 2025-10-22 | — | — | EP | disclosed |
| US-20250171447-A1 | ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2025-05-29 | — | — | US | disclosed |
| EP-4539840-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | Neuron23, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| CN-119730846-A | Kinase modulators and methods of use thereof | 神经元23公司 | 2025-03-28 | — | — | CN | disclosed |
| US-5698548-A | Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents | SCHERING CORPORATION (US) | 1997-12-16 | — | — | US | disclosed |
| EP-0614888-B1 | Tetrahydrocyclopent[b]indole methanamines and related compounds, a process for their preparation and their use as medicaments | HOECHST MARION ROUSSEL INC (US) | 1997-05-07 | — | — | EP | disclosed |
| US-5532233-A | PLATELET ACTIVATING FACTOR ANTAGONIST | BOEHRINGER INGELHEIM KG (DE) | 1996-07-02 | — | — | US | disclosed |
| EP-0681569-A1 | SPIROCYCLOALKYL-SUBSTITUTED AZETIDINONES USEFUL AS HYPOCHOLESTEROLEMIC AGENTS | SCHERING CORPORATION (US) | 1995-11-15 | — | — | EP | disclosed |
| US-5350762-A | Alzheimer's | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1994-09-27 | — | — | US | disclosed |
| EP-0614888-A1 | Tetrahydrocyclopent[b]indole methanamines and related compounds, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1994-09-14 | — | — | EP | disclosed |
| WO-1994017038-A1 | SPIROCYCLOALKYL-SUBSTITUTED AZETIDINONES USEFUL AS HYPOCHOLESTEROLEMIC AGENTS | SCHERING CORPORATION (US) | 1994-08-04 | — | — | WO | disclosed |
| EP-0549598-A1 | 2-METHYLIMIDAZO[4,5-c]PYRIDINE DERIVATIVES AND THERAPEUTIC AGENTS | Pfizer Limited (GB) | 1993-07-07 | — | — | EP | disclosed |
| WO-1992003434-A1 | THERAPEUTIC AGENTS | PFIZER LIMITED (GB) | 1992-03-05 | — | — | WO | disclosed |
| US-4009181-A | ANTIINFLAMMATORY AGENTS, ANALGESICS, ANTIRHEUMATIC AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1977-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171447-A1 | ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE THEREOF | ADORA2A, ADORA2B, ADORA1 | PDK1 1609/4885ALDH1A1 483/4885MAPT 4454/4885 |
| US-20260132109-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, IRF3, CGAS | PDK1 4240/4885ALDH1A1 3829/4885MAPT 3909/4885 |
| US-12528781-B2 | Heterocyclic GLP-1 agonists | GLP1R, GIPR, VIP | PDK1 1191/4885ALDH1A1 3780/4885MAPT 3404/4885 |
| US-12503436-B2 | Compounds and compositions for treating conditions associated with STING activity | STING1, CGAS, IRF3 | PDK1 3012/4885ALDH1A1 4654/4885MAPT 3027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.